Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: USA Healthcare VC Firm Invests Up to $25M in Therapeutics Companies in Oncology & Platform Technologies Across the Globe

2 Jul

A healthcare investment firm with offices in USA  actively finds and invests in life sciences companies (both public and private) that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. The firm makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm considers investments into companies located anywhere around the globe.

The firm invests in breakthrough therapeutics, with a focus on oncology. However, the firm also considers investments into companies developing platform technologies. While the firm considers investment from seed stage to private investment in public equity, the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.

The firm invests primarily in private companies but will also consider private investment in public equity opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Investment Firm Seeks Opportunities in Therapeutics, Medical Devices, and Diagnostics in USA & China

2 Jul

A private investment firm based in China was formed by professionals with R&D, entrepreneurial and investment experiences in both China and the US. The firm currently investing from its 300 million RMB (US$50 million) fund into early stage ventures in the life sciences and healthcare sector. Typical allocation size ranges from US$0.5-5 million. The firm can either lead or follow in a financing round. The firm is seeking opportunities from China and the US.

The firm works on a wide range of life science sectors including biopharmaceuticals, medical devices, diagnostics, life science R&D, and medical services. The firm is especially interested in clinical stage molecular diagnostic products, while it would also consider preclinical stage projects with a lesser interest. The firm is agnostic to disease indications.

The firm is looking for experienced management team with proven products. The firm can assist with registration and distribution in China by leveraging its network of pharma partners, CRO/CMO, academic centers, and distribution channels. The firm is interested in distribution rights in China and may request board representation on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Investment Firm Funds Clinical Trials of Biotech Companies, Open to Considering Medical Devices, Diagnostics, Digital Health

2 Jul

A firm with offices throughout USA, Western Europe, and Asia invests specifically in companies that are raising funds to carry out clinical trials which can be performed, totally or in part, in an affiliated network of sites located in Europe and Asia. The firm typically invests alongside lead investors with a track record in biotech or medtech, and usually funds a large fraction of clinical trial costs. The firm can fund up to 10-15 trials per year. The size of investments is flexible, scaled to the clinical trial requirements, and will mostly range from 1 to 6 million USD/EUR. Investments made by the firm will fund work performed by a top-tier FDA-inspected network of sites offering clinical studies and CRO services to major pharma companies.

Although focused primarily on therapeutics, the firm will also consider diagnostics, medical devices, and digital health companies. The firm is generally indication-agnostic but has a keen interest in fields such as diabetes, pulmonology, ophthalmology and some cancers. The firm is primarily interested in companies running Phase I / Phase II clinical trials or equivalent.

The firm looks to act as a co-investor and will typically not require a board seat. The firm will more often invest when there is a lead investor on board. The firm has no specific requirements for the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Leading Investment Firm in China Seeks USA-Based Opportunities Across All Life Science Sectors with a USA-Dedicated Fund

2 Jul

A leading investment bank and investment fund headquartered in China is currently interested in investing in privately held companies in the Healthcare sector. The firm currently manages two funds, one of which only invests in China, and another early-stage fund that focuses on investments into US start-ups. The firm is planning to raise a second and much larger US fund in next 12 months. On average, the initial size of investment is in the $2-3M range.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, genomics, healthcare services and healthcare IT companies. With respect to medical devices, the firm is interested in devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled devices.

The firm prefers to act as the lead investor but is also open to co-investing. The firm will neither seek a board seat nor seek distribution rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based Biotech Focused VC Invests Up to $6M in Early Stage Therapeutics Companies in All Indications

25 Jun

A China-based VC focused exclusively on the biotech industry combines a deep understanding of drug development, industry networks, as well as regulatory expertise to help portfolio companies to achieve strategic goals efficiently. The partners of the fund have combined decades of drug industry experiences before establishing the firm in 2019. The fund invests in true innovations with a major impact on patients’ lives. The firm’s investment size can range from $1 M and up to $6 M, in which the typical size would be $3 M~$4 M. The firm is actively looking for new investment opportunities in North America and Europe. The firm can act as lead or co-investor.

Within biotech, the firm focuses on companies in pre-IND to phase II. The firm is opportunistic in all indications and willing to consider orphan indications.

The firm has no specific requirements for companies. The firm generally takes a board seat or an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Paris-Based VC Firm Invests in Various Life Science Sectors, Focusing on Companies Located in France & Western Europe

25 Jun

A VC firm based in Paris invests primarily in seed/series A with significant follow-on capability.

The firm is now investing with two funds; the first fund is dedicated to investing in companies based in the Paris region across various sectors (digital, deeptech, life science), while the second fund is dedicated to investing in Digital Health companies in Western Europe. The firm generally invests between 0.3-1.5M EUR in the initial investment, and can invest up to 2-5M EUR overall in a company, and will invest in up to 10 companies a year.

The firm invests differently from their two current funds :

– The first fund is sector agnostic, and will invest in Life Science (therapeutics, diagnostics, devices and digital health companies) in the Paris region.
– The second fund covering Western Europe is focused primarily on digital health, due to the strategic interest of the fund investors in this area (several healthcare companies)

The firm can lead or co-invest, and do frequently lead. They will take a board seat in any case – the firm is an active investor providing hands-on support to its portfolio company (Strategy, HR, Financing, …).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Investment Firm Seeks Global Opportunities in Medical Devices, Diagnostics, and Digital Health, Investing Up to $10M

25 Jun

A venture capital firm founded in 2020 and based in USA is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with check sizes between 5 – 10 million USD. The firm prefers to lead the financing rounds but is open to co-investing. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: